Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I am holding and not going to panic sell like so many people are doing. The Canadian cannibis companies are not affected by Jeff Sessions thinking. We have Canada and the World. Don’t Panic over one news release. The states US attorney Generals are being able to decide for their states.
Great Green Day.
I wonder how much CanniMed paid them to post that article? If you are scared then take your profits and move on IMO. The fundamentals are rock solid and yes it is moving up quickly and there is some hype but there is solid fun damentals and a bright future ahead for $ACBFF. Everyone should do your own DD and then go with your head or gut. Whichever works best for you. For me I am long and strong $ACBFF Good luck to all!
Another great Green day with $ACBFF. Someone needs to update the charts on the opening board here with ACBFF. We need any new comers or people looking to buy to see a good up-to-date chart. IMHO
Hopefully we will continue to move up and everyone remains long and not be selling and taking profits. I am all about taking profits but it is very risky to cash out and then get back in with the same or more shares. I always come up short and miss moves. By holding my long position I will always be in on big moves upward. Long and strong $ACBFF
Oh yeah. What a green opening. Very good day for $ACBFF
Aurora Cannabis Calls for Additional Disclosure from CanniMed on ''Bizarre'' Newstrike Supply Agreement
BY Canada NewsWire
— 7:00 AM ET 01/03/2018
TSX: ACB
EDMONTON, Jan. 3, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") today called for additional disclosure on yesterday's wholly inadequate announcement by CanniMed Therapeutics Inc. ("CanniMed") of a supply agreement (the "Supply Agreement") with Up Cannabis Inc. ("UCI"), a subsidiary of Newstrike Resources Ltd ("Newstrike"), CanniMed's proposed acquisition candidate.
The timing of the Supply Agreement suggests no strategic rationale, and raises serious questions about the apparent ongoing failure of CanniMed's management and Board to meet their fiduciary responsibilities to their shareholders, in view of the superior offer from Aurora (the "Offer") (described below) to CanniMed shareholders.
"Simply put, this is a bizarre action by CanniMed management," said Cam Battley, Executive Vice President of Aurora. "Why would CanniMed sign a supply agreement with a company they have proposed to acquire in three weeks? Why would they sign a supply agreement with a company that doesn't have a sales license, and therefore has no ability to fulfill the agreement? If CanniMed needed to purchase wholesale product, they could easily have signed a supply agreement with any number of producers currently licensed to sell. CanniMed has never previously entered into a wholesale supply agreement, nor ever indicated that they needed additional supply. So it's reasonable to ask whether their announcement actually meets the definition of a supply agreement as commonly understood – or whether it represents a disguised scheme to achieve other objectives. It's clear based on publicly disclosed information that Newstrike is in urgent financial need. Is this an attempt to transfer CanniMed capital sufficient to keep the lights on and the doors open at Newstrike? Alternatively, is this an attempt to entrench a relationship between CanniMed and Newstrike under adverse terms that are counter to the interests of CanniMed shareholders, as the latest attempt at creating a poison pill? Given that CanniMed shareholders are due to decide in the next few weeks on both the proposed CanniMed-Newstrike transaction and the Aurora Offer to acquire CanniMed, Aurora believes it is incumbent on CanniMed management to disclose the terms of the supply agreement they have signed with Newstrike's Up Cannabis subsidiary."
At a minimum, CanniMed must let investors know what consideration was paid for the Supply Agreement, what price product will be purchased at, the expected timing of deliveries under the Supply Agreement, what the conditions are for the renewal of the Supply Agreement, and what are the terms and conditions upon which the Supply Agreement may be terminated. Aurora looks forward to CanniMed's additional disclosure, and the filing of what is clearly a material agreement on SEDAR.
Aurora has serious concerns, based on the minimal terms currently disclosed, that the Supply Agreement is not attractive from a financial or business perspective. Without clear and adequate public disclosure of the key terms of the Supply Agreement, Aurora believes CanniMed shareholders will be unable to assess the full financial impact, and are likely to be misled by statements from CanniMed management.
If the Aurora Offer is successful, Aurora will review all agreements entered into by CanniMed to ensure that they are reached on commercially reasonable terms, and reserves the right to terminate any agreements entered into by CanniMed during the currency of the Offer. Aurora is also prepared to hold CanniMed officers and directors accountable for value destroying transactions entered into while the Aurora Offer is outstanding.
About the Offer
On November 24, 2017, Aurora formally commenced its Offer to purchase all of the issued and outstanding common shares of CanniMed for consideration consisting of common shares of Aurora. The Offer Document, including the takeover bid circular and related documents are available on SEDAR.
The Offer Documents are also available on Aurora's website at www.auroramj.com and shareholders are invited to visit cannimed.auroramj.com for further information.
How to Tender
Aurora encourages CanniMed shareholders to read the full details of the Offer set forth in the takeover bid circular and accompanying offer documents, (collectively, the "Offer Documents"), which contain detailed instructions on how CanniMed shareholders can tender their CanniMed common shares to the Offer. For assistance in depositing CanniMed common shares to the Offer, CanniMed shareholders should contact the depositary and the Information Agent for the Offer, Laurel Hill Advisory Group at Phone: 1-877-452-7184 (North American Toll Free Phone) and 1-416-304-0211 (Outside North America); Facsimile: 416-646-2415; and E-mail: assistance@laurelhill.com.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.
In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".
On behalf of the Boards of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release, including assumptions based upon CanniMed's publicly disclosed information, and that there will be no change in the business, prospects or capitalization of CanniMed or Aurora. In particular, this news release contains forward-looking information concerning: (i) the Offer, various terms of the Offer and the anticipated timing of completion of the Offer; (ii) expectations with respect to synergies and efficiencies that may be achieved upon a combination of the businesses of Aurora and CanniMed and other benefits of a combination of the businesses of Aurora and CanniMed; and (iii) anticipated actions of Aurora following successful completion of the Offer. The information concerning CanniMed contained in this news release has been taken from, or is based upon, publicly available information filed by CanniMed with securities regulatory authorities in Canada prior to the date of this news release and other public sources.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc. ( ACBFF )
$IMLFF
InMed Pharmaceuticals Is More Than Just Another Cannabis Drug Company
https://www.forbes.com/sites/debraborchardt/2017/03/21/inmed-pharmaceuticals-is-more-than-just-another-cannabis-drug-company/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo#2bf4375b3b22
Aurora Cannabis Calls for Additional Disclosure from CanniMed on ''Bizarre'' Newstrike Supply Agreement
BY Canada NewsWire
— 7:00 AM ET 01/03/2018
TSX: ACB
EDMONTON, Jan. 3, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") today called for additional disclosure on yesterday's wholly inadequate announcement by CanniMed Therapeutics Inc. ("CanniMed") of a supply agreement (the "Supply Agreement") with Up Cannabis Inc. ("UCI"), a subsidiary of Newstrike Resources Ltd ("Newstrike"), CanniMed's proposed acquisition candidate.
The timing of the Supply Agreement suggests no strategic rationale, and raises serious questions about the apparent ongoing failure of CanniMed's management and Board to meet their fiduciary responsibilities to their shareholders, in view of the superior offer from Aurora (the "Offer") (described below) to CanniMed shareholders.
"Simply put, this is a bizarre action by CanniMed management," said Cam Battley, Executive Vice President of Aurora. "Why would CanniMed sign a supply agreement with a company they have proposed to acquire in three weeks? Why would they sign a supply agreement with a company that doesn't have a sales license, and therefore has no ability to fulfill the agreement? If CanniMed needed to purchase wholesale product, they could easily have signed a supply agreement with any number of producers currently licensed to sell. CanniMed has never previously entered into a wholesale supply agreement, nor ever indicated that they needed additional supply. So it's reasonable to ask whether their announcement actually meets the definition of a supply agreement as commonly understood – or whether it represents a disguised scheme to achieve other objectives. It's clear based on publicly disclosed information that Newstrike is in urgent financial need. Is this an attempt to transfer CanniMed capital sufficient to keep the lights on and the doors open at Newstrike? Alternatively, is this an attempt to entrench a relationship between CanniMed and Newstrike under adverse terms that are counter to the interests of CanniMed shareholders, as the latest attempt at creating a poison pill? Given that CanniMed shareholders are due to decide in the next few weeks on both the proposed CanniMed-Newstrike transaction and the Aurora Offer to acquire CanniMed, Aurora believes it is incumbent on CanniMed management to disclose the terms of the supply agreement they have signed with Newstrike's Up Cannabis subsidiary."
At a minimum, CanniMed must let investors know what consideration was paid for the Supply Agreement, what price product will be purchased at, the expected timing of deliveries under the Supply Agreement, what the conditions are for the renewal of the Supply Agreement, and what are the terms and conditions upon which the Supply Agreement may be terminated. Aurora looks forward to CanniMed's additional disclosure, and the filing of what is clearly a material agreement on SEDAR.
Aurora has serious concerns, based on the minimal terms currently disclosed, that the Supply Agreement is not attractive from a financial or business perspective. Without clear and adequate public disclosure of the key terms of the Supply Agreement, Aurora believes CanniMed shareholders will be unable to assess the full financial impact, and are likely to be misled by statements from CanniMed management.
If the Aurora Offer is successful, Aurora will review all agreements entered into by CanniMed to ensure that they are reached on commercially reasonable terms, and reserves the right to terminate any agreements entered into by CanniMed during the currency of the Offer. Aurora is also prepared to hold CanniMed officers and directors accountable for value destroying transactions entered into while the Aurora Offer is outstanding.
About the Offer
On November 24, 2017, Aurora formally commenced its Offer to purchase all of the issued and outstanding common shares of CanniMed for consideration consisting of common shares of Aurora. The Offer Document, including the takeover bid circular and related documents are available on SEDAR.
The Offer Documents are also available on Aurora's website at www.auroramj.com and shareholders are invited to visit cannimed.auroramj.com for further information.
How to Tender
Aurora encourages CanniMed shareholders to read the full details of the Offer set forth in the takeover bid circular and accompanying offer documents, (collectively, the "Offer Documents"), which contain detailed instructions on how CanniMed shareholders can tender their CanniMed common shares to the Offer. For assistance in depositing CanniMed common shares to the Offer, CanniMed shareholders should contact the depositary and the Information Agent for the Offer, Laurel Hill Advisory Group at Phone: 1-877-452-7184 (North American Toll Free Phone) and 1-416-304-0211 (Outside North America); Facsimile: 416-646-2415; and E-mail: assistance@laurelhill.com.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.
In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".
On behalf of the Boards of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release, including assumptions based upon CanniMed's publicly disclosed information, and that there will be no change in the business, prospects or capitalization of CanniMed or Aurora. In particular, this news release contains forward-looking information concerning: (i) the Offer, various terms of the Offer and the anticipated timing of completion of the Offer; (ii) expectations with respect to synergies and efficiencies that may be achieved upon a combination of the businesses of Aurora and CanniMed and other benefits of a combination of the businesses of Aurora and CanniMed; and (iii) anticipated actions of Aurora following successful completion of the Offer. The information concerning CanniMed contained in this news release has been taken from, or is based upon, publicly available information filed by CanniMed with securities regulatory authorities in Canada prior to the date of this news release and other public sources.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc. ( ACBFF
Loading...
Loading...
)
Aurora Cannabis Calls for Additional Disclosure from CanniMed on ''Bizarre'' Newstrike Supply Agreement
BY Canada NewsWire
— 7:00 AM ET 01/03/2018
TSX: ACB
EDMONTON, Jan. 3, 2018 /CNW/ - Aurora Cannabis Inc. ("Aurora") today called for additional disclosure on yesterday's wholly inadequate announcement by CanniMed Therapeutics Inc. ("CanniMed") of a supply agreement (the "Supply Agreement") with Up Cannabis Inc. ("UCI"), a subsidiary of Newstrike Resources Ltd ("Newstrike"), CanniMed's proposed acquisition candidate.
The timing of the Supply Agreement suggests no strategic rationale, and raises serious questions about the apparent ongoing failure of CanniMed's management and Board to meet their fiduciary responsibilities to their shareholders, in view of the superior offer from Aurora (the "Offer") (described below) to CanniMed shareholders.
"Simply put, this is a bizarre action by CanniMed management," said Cam Battley, Executive Vice President of Aurora. "Why would CanniMed sign a supply agreement with a company they have proposed to acquire in three weeks? Why would they sign a supply agreement with a company that doesn't have a sales license, and therefore has no ability to fulfill the agreement? If CanniMed needed to purchase wholesale product, they could easily have signed a supply agreement with any number of producers currently licensed to sell. CanniMed has never previously entered into a wholesale supply agreement, nor ever indicated that they needed additional supply. So it's reasonable to ask whether their announcement actually meets the definition of a supply agreement as commonly understood – or whether it represents a disguised scheme to achieve other objectives. It's clear based on publicly disclosed information that Newstrike is in urgent financial need. Is this an attempt to transfer CanniMed capital sufficient to keep the lights on and the doors open at Newstrike? Alternatively, is this an attempt to entrench a relationship between CanniMed and Newstrike under adverse terms that are counter to the interests of CanniMed shareholders, as the latest attempt at creating a poison pill? Given that CanniMed shareholders are due to decide in the next few weeks on both the proposed CanniMed-Newstrike transaction and the Aurora Offer to acquire CanniMed, Aurora believes it is incumbent on CanniMed management to disclose the terms of the supply agreement they have signed with Newstrike's Up Cannabis subsidiary."
At a minimum, CanniMed must let investors know what consideration was paid for the Supply Agreement, what price product will be purchased at, the expected timing of deliveries under the Supply Agreement, what the conditions are for the renewal of the Supply Agreement, and what are the terms and conditions upon which the Supply Agreement may be terminated. Aurora looks forward to CanniMed's additional disclosure, and the filing of what is clearly a material agreement on SEDAR.
Aurora has serious concerns, based on the minimal terms currently disclosed, that the Supply Agreement is not attractive from a financial or business perspective. Without clear and adequate public disclosure of the key terms of the Supply Agreement, Aurora believes CanniMed shareholders will be unable to assess the full financial impact, and are likely to be misled by statements from CanniMed management.
If the Aurora Offer is successful, Aurora will review all agreements entered into by CanniMed to ensure that they are reached on commercially reasonable terms, and reserves the right to terminate any agreements entered into by CanniMed during the currency of the Offer. Aurora is also prepared to hold CanniMed officers and directors accountable for value destroying transactions entered into while the Aurora Offer is outstanding.
About the Offer
On November 24, 2017, Aurora formally commenced its Offer to purchase all of the issued and outstanding common shares of CanniMed for consideration consisting of common shares of Aurora. The Offer Document, including the takeover bid circular and related documents are available on SEDAR.
The Offer Documents are also available on Aurora's website at www.auroramj.com and shareholders are invited to visit cannimed.auroramj.com for further information.
How to Tender
Aurora encourages CanniMed shareholders to read the full details of the Offer set forth in the takeover bid circular and accompanying offer documents, (collectively, the "Offer Documents"), which contain detailed instructions on how CanniMed shareholders can tender their CanniMed common shares to the Offer. For assistance in depositing CanniMed common shares to the Offer, CanniMed shareholders should contact the depositary and the Information Agent for the Offer, Laurel Hill Advisory Group at Phone: 1-877-452-7184 (North American Toll Free Phone) and 1-416-304-0211 (Outside North America); Facsimile: 416-646-2415; and E-mail: assistance@laurelhill.com.
About Aurora
Aurora's wholly-owned subsidiary, Aurora Cannabis Enterprises Inc., is a licensed producer of medical cannabis pursuant to Health Canada's Access to Cannabis for Medical Purposes Regulations ("ACMPR"). The Company operates a 55,200 square foot, state-of-the-art production facility in Mountain View County, Alberta, known as "Aurora Mountain", a second 40,000 square foot high-technology production facility known as "Aurora Vie" in Pointe-Claire, Quebec on Montreal's West Island, and is currently constructing an 800,000 square foot production facility, known as "Aurora Sky", at the Edmonton International Airport, as well as is completing a fourth facility in Lachute, Quebec through its wholly owned subsidiary Aurora Larssen Projects Ltd.
In addition, the Company holds approximately 17.23% of the issued shares in leading extraction technology company Radient Technologies Inc., based in Edmonton, and is in the process of completing an investment in Edmonton-based Hempco Food and Fiber for an ownership stake of up to 50.1%. Furthermore, Aurora is the cornerstone investor with a 22.9% stake in Cann Group Limited, the first Australian company licensed to conduct research on and cultivate medical cannabis. Aurora also owns Pedanios, a leading wholesale importer, exporter, and distributor of medical cannabis in the European Union, based in Germany. The Company offers further differentiation through its acquisition of BC Northern Lights Ltd. and Urban Cultivator Inc., industry leaders, respectively, in the production and sale of proprietary systems for the safe, efficient and high-yield indoor cultivation of cannabis, and in state-of-the-art indoor gardening appliances for the cultivation of organic microgreens, vegetables and herbs in home and professional kitchens. Aurora's common shares trade on the TSX under the symbol "ACB".
On behalf of the Boards of Directors,
AURORA CANNABIS INC.
Terry Booth
CEO
This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release, including assumptions based upon CanniMed's publicly disclosed information, and that there will be no change in the business, prospects or capitalization of CanniMed or Aurora. In particular, this news release contains forward-looking information concerning: (i) the Offer, various terms of the Offer and the anticipated timing of completion of the Offer; (ii) expectations with respect to synergies and efficiencies that may be achieved upon a combination of the businesses of Aurora and CanniMed and other benefits of a combination of the businesses of Aurora and CanniMed; and (iii) anticipated actions of Aurora following successful completion of the Offer. The information concerning CanniMed contained in this news release has been taken from, or is based upon, publicly available information filed by CanniMed with securities regulatory authorities in Canada prior to the date of this news release and other public sources.
Neither TSX nor its Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE Aurora Cannabis Inc. ( ACBFF
Loading...
Loading...
)
Hoping for a GREEN opening. $CBWTF long and strong. Great buy while it's below $2.00ps. Get it while you can should bread into $2.00 area today and continue it's movement up, up and away. $CBWTF GLTA
California MJ market moving ahead but we in the US need our Federal Government to pass laws supporting states that have voted to legalize MJ and ease banking laws, enforcement regulations etc. Here's a article I just found. A good read concerning MJ and the US and our MJ Industry.
https://www.marketwatch.com/story/cannabis-related-stocks-rally-as-marijuana-sales-go-mainstream-in-california-2018-01-02?siteid=yhoof2&yptr=yahoo
California MJ market moving ahead but we in the US need our Federal Government to pass laws supporting states that have voted to legalize MJ and ease banking laws, enforcement regulations etc. Here's a article I just found. A good read concerning MJ and the US and our MJ Industry.
https://www.marketwatch.com/story/cannabis-related-stocks-rally-as-marijuana-sales-go-mainstream-in-california-2018-01-02?siteid=yhoof2&yptr=yahoo
A must read article on Aurora and CanniMed actions.
https://www.newcannabisventures.com/aurora-cannabis-questions-acquisition-target-cannimeds-supply-agreement-with-newstrike/
A must read article on Aurora and CanniMed actions.
https://www.newcannabisventures.com/aurora-cannabis-questions-acquisition-target-cannimeds-supply-agreement-with-newstrike/
$CBWTF up 25% today.
Onward and upward.
Long and strong $CBWTF
$CBWTF up 25% today.
Onward and upward.
Long and strong $CBWTF
$CBWTF up 25% today.
Onward and upward.
Long and strong $CBWTF
$CBWTF up 25% today.
Onward and upward.
Long and strong $CBWTF
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
Marijuana Stocks that are and will make you a ton of $$$$$$
$MJNA
$MCOA
$MCIG
$ACBFF
$CBWTF
$IMLFF
$PAOG
$LBTD
$FFRMF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
$CBWTF This company will be as large as Auroa, Canopy and Aphria. Buy in below $2.00 while you can, Check our our message board $CBWTF
The news just keeps coming and gets better and better on $ACBFF
https://www.newcannabisventures.com/aurora-cannabis-reports-november-sales-of-3-1-million-and-more-than-500-million-cash-and-marketable-securities/
I agree Swin. This is just the beginning. For me I am LONG and STRONG on $ACBFF. Buy on the dips but hold on to your shares and this way you won't miss out on any big moves upward. So people sell when they are at 20%+ profit which I understand taking profits. But for me I have never been able to time it right as to get in and out and back in without loosing shares or profits. So I do my DD and go with the info I have and just sit back and enjoy the ride. Could I maybe add some more shares my selling and buying back in? Maybe, but it's risky and considering the capital gains taxes you have to pay if you don't hold your positions for a year must be considered. IMHO Long and strong $ACBFF
$ACBFF Here's a news clip that I saw and thought it was interesting.
https://www.newcannabisventures.com/be-prepared-for-consolidation-in-the-canadian-cannabis-sector-in-2018/
$CBWTF $Cannabis Wheaton Income Corp.
Now it's time for the second major wave leading up to full legalization. And this one's going to be a doozie. Right now, I can really only think of one marijuana stock that is undervalued when compared to the competition: Cannabis Wheaton Income Corp. A relative newcomer to the scene, Cannabis Wheaton is led by a team of established industry experts. Their CEO, Chuck Rifici, is the former CEO of Tweed (ie. Canopy Growth) and the former CFO of the Liberal Party. Cannabis Wheaton was also recently awarded Startup of the Year by Lift.co, and Rifici was awarded Innovator of the Year.
Cannabis Wheaton's streaming model allows it to scale up much quicker than any of the other LPs. CBW's current projected grow space easily eclipses both Aphria and Aurora's square footage combined. At last count, CBW is getting ramped up for at least 2.5 million square feet of marijuana production in the near future, which is more than double what Aphria and Aurora each project individually. Aurora Cannabis, for example, currently operates under 100,000 square feet and keeps pushing back the launch date for their white elephant Aurora Sky project at 800,000 square feet, making it possibly the most overvalued marijuana stock right now. In contrast, with its new deal with FV Pharma, Cannabis Wheaton is now poised to develop the single largest marijuana growing facility in the world as but one of the almost 20 investment deals in its portfolio. The first phase of the FV Pharma operation may actually be online before Aurora Sky!
If you want to know more about Cannabis Wheaton, you can follow other posts and look up the news on the latest deals that helped push the stock price from $0.86 to a new high of $2.02 [+135%] in the final trading days of 2017. The latest deal with FV Pharma and the licensing agreement with a cannabis testing company also demonstrate that the team at Cannabis Wheaton is very serious about contending for the #1 spot in this marijuana race. With product already coming in as of 2018, CBW will be well poised to take full advantage of the coming recreational market. I also have a sneaking suspicion that Cannabis Wheaton may be part of some of the larger MOUs that will surely be announced by Quebec, Ontario, and British Columbia in the coming months.
That being said, if you bought $5500 of Cannabis Wheaton at last Friday's close, you could have picked up 3200 shares at $1.71. But I don't think you will have that opportunity much longer. Cannabis Wheaton's current market cap is $451M, which compares quite humbly against Canopy Growth at $5.6B and Aphria at $2.8B. Aurora's market cap of $4.4B places it at a whopping 134X current earnings. If anything goes wrong or gets delayed with Aurora Sky, their share price will plummet. A lot will be revealed about these companies as the next quarterly reports come through in 2018.
Cannabis Wheaton, of course, does not have earnings to report in 2017 since they have only been trading since last May unlike the other major players who have been around for a few years. Remember, Canopy Growth has been trading as Tweed since 2014. It took them quite a while to get where they are. But 2018 looks strong for Cannabis Wheaton. Rifici & Co. are aggressively committed to giving Bruce Linton and Tweed a run for their money. And the money is about to start pouring in to Cannabis Wheaton.
Based on the overall trends in the marijuana market so far, I conservatively expect the share price of CBW to easily jump anywhere from $10-20 this year. While the bulk of marijuana stocks are set to gain in 2018, I think the best opportunity for investors right now is by far Cannabis Wheaton. If you can still pick up those 3200 shares at $1.71, when the company reaches a valuation of even $3B, you'd have a share price of $11.37. That's a tax free gain of $30,000 on a $5500 investment. But seeing as CBW is poised to actually contend with Canopy Growth, the upside over the next 1-3 years is definitely much more than that. While just about any of the marijuana stocks will likely earn you money in 2018, I think investors stand to profit the most with Cannabis Wheaton looking ahead to 2019.
For more follow information I find on this stock and other stocks DD you can follow me on my Investorhub account. Here's wishing everyone a Happy New Year and here's to keeping it LONG & GREEN! $CBWTF[color=red][/color]
Here's an article I just read and thought everyone would like to read. Great News. $ACBFF
https://www.newcannabisventures.com/aurora-cannabis-canvasrx-clinics-gains-exclusive-use-of-namastemd-patient-acquisition-tool-in-canada-under-private-label/
My guess would be around $5.00 to $8.00 with good revenues and aggressive moves by the management team. I do believe there will be a lot of early on profit taking but I am long and will buy on the dips. That is what I did with $ACBFF. $CWBTF will make us all $$$ if we buy and hold. I am in for making BIG $$$$.
The fundamentals are strong and should be a great investment. $CBWTF
I pulled the trigger also. Wasn’t able to buy this morning and went against my gut chasing a stock upwards. But hopefully got in below $2.00 @ $1.72. Now watch it go down. Lol. Hopefully tomorrow will continue its climb upwards. I am long anyway so will see how it goes.
At least it caused a positive run up and not down. Hopefully more positive news to follow. Happy New Year to everyone. $KALTF.
Thanks for the great information and article on $KALTF. Any idea as to reachable future $$ pps upside? Didn’t know if they still have a lot more legs or if they’ve reached their potential numbers. Hoping that they’ve only begun with their journey upward climb to the top. Long on $KALTF
Happy New Year to everyone. Long and strong with $KALTF.